USA - NASDAQ:AIMD - US00902F4028 - Common Stock
The current stock price of AIMD is 3.26 USD. In the past month the price decreased by -18.7%. In the past year, price increased by 35.89%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| AAPL | APPLE INC | 36.16 | 4008.98B | ||
| DELL | DELL TECHNOLOGIES -C | 19.08 | 102.15B | ||
| STX | SEAGATE TECHNOLOGY HOLDINGS | 30.2 | 58.73B | ||
| WDC | WESTERN DIGITAL CORP | 24.37 | 54.88B | ||
| PSTG | PURE STORAGE INC - CLASS A | 58.09 | 31.88B | ||
| HPE | HEWLETT PACKARD ENTERPRISE | 12.54 | 31.28B | ||
| SNDK | SANDISK CORP | N/A | 31.72B | ||
| SMCI | SUPER MICRO COMPUTER INC | 25.17 | 24.98B | ||
| HPQ | HP INC | 8.51 | 24.90B | ||
| NTAP | NETAPP INC | 15.94 | 23.09B | ||
| LOGI | LOGITECH INTERNATIONAL-REG | 22.72 | 19.11B | ||
| IONQ | IONQ INC | N/A | 19.25B |
Ainos, Inc. is a diversified medtech company, which engages in the development of medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. The company is headquartered in San Diego, California and currently employs 44 full-time employees. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. The company is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions.
AINOS INC
8880 Rio San Diego Drive, Ste. 800
San Diego CALIFORNIA US
Employees: 44
Phone: 18588692986
Ainos, Inc. is a diversified medtech company, which engages in the development of medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. The company is headquartered in San Diego, California and currently employs 44 full-time employees. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. The company is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions.
The current stock price of AIMD is 3.26 USD. The price decreased by -0.61% in the last trading session.
AIMD does not pay a dividend.
AIMD has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
AINOS INC (AIMD) operates in the Information Technology sector and the Technology Hardware, Storage & Peripherals industry.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AIMD.
AINOS INC (AIMD) currently has 44 employees.
ChartMill assigns a technical rating of 3 / 10 to AIMD. When comparing the yearly performance of all stocks, AIMD is one of the better performing stocks in the market, outperforming 82.97% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to AIMD. AIMD may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months AIMD reported a non-GAAP Earnings per Share(EPS) of -5.27. The EPS increased by 66.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.73% | ||
| ROE | -137.42% | ||
| Debt/Equity | 0.96 |